Motor Neurone Disease Trial, Recruiting NCT06450691 Sponsor: Assistance Publique - Hôpitaux de Paris Condition: Motor Neurone Disease
Back to Motor Neurone Disease

Motor Neurone Disease Trial, Recruiting

NCT06450691
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are an adult (any gender) who is willing to give written consent to take part in the study
  • You are covered by a social security (health insurance) scheme
  • If you have ALS: You have been diagnosed with ALS using established medical criteria, and either have a family history of ALS, carry a known gene mutation linked to ALS, developed symptoms before age 30, or have a non-inherited form of ALS
  • If you carry an ALS-related gene mutation: You carry a gene mutation known to cause ALS but have not yet developed any symptoms
  • If you are a healthy volunteer: You are a healthy person who can be matched by age and gender to serve as a comparison participant

Who may not be able to join:

  • You have a known skin condition (such as acne, eczema, psoriasis, melanoma, skin cancer, rosacea, or scabies) that the doctor feels would make a skin biopsy (small skin sample) unsafe for you
  • A recent blood test (within the last 3 months) shows your platelet count (cells that help blood clot) is below 75,000/mm³
  • You have a known allergy to lidocaine or prilocaine (local anaesthetic medicines used to numb the skin)
  • You are currently pregnant or breastfeeding
  • You are under legal guardianship or a similar form of legal protection
  • Your overall health condition makes it unsuitable for you to have a skin sample taken, in the opinion of the doctor running the trial
  • You are already taking part in another clinical drug trial or study that would interfere with this one

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 27 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Phone: 33142162472

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
28 August 2025
Est. completion
1 September 2034

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Detection of cytoplasmic TDP-43, TIA1 and/or p62 aggregates in patient fibroblasts

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov